Balaji

Alagar K. Balaji, Salt Lake City, UT US

Patent application number	Description	Published
20100199909	SYSTEMS AND METHODS FOR RECYCLING SEMICONDUCTOR MATERIAL REMOVED FROM A RAW SEMICONDUCTOR BOULE - Methods of recycling excess semiconductor material removed from an unshaped semiconductor boule are disclosed. Excess semiconductor material is cut from an semiconductor unshaped boule thereby generating a shaped semiconductor boule. The excess semiconductor material is removed in the form of large pieces that can easily be cleaned and retrieved for reuse.	08-12-2010
20110118751	Integrated Surgical Cutting System - Integrated surgical systems and methods for using same are provided that can receive scanned images and produce a three dimensional model from the images. Based at least in pan on the three dimensional model, a processor generates code defining an optimized tool path, which is sent to a surgical machining system that can machine the desired portion of the patient. In one exemplary aspect, the integrated system operates in a clearly defined and pre-programmed manner with no necessity for in-situ sensory or guidance feedback.	05-19-2011
20150157413	INTEGRATED SURGICAL CUTTING SYSTEM - Integrated surgical systems and methods for using same are provided that can receive scanned images and produce a three dimensional model from the images. Based at least in part on the three dimensional model, a processor generates code defining an optimized tool path, which is sent to a surgical machining system that can machine the desired portion of the patient. In one exemplary aspect, the integrated system operates in a clearly defined and pre-programmed manner with no necessity for in-situ sensory or guidance feedback.	06-11-2015

Alagar Krishnan Balaji, Salt Lake City, UT US

Patent application number	Description	Published
20140196273	SYSTEM AND METHOD FOR DISPENSING A MINIMUM QUANTITY OF CUTTING FLUID - Devices, systems, and methods are provided for controlling a quantity of cutting fluid dispensed for a cutting tool within a CNC or other machining system. The devices, systems, and methods may include controlling multiple fluids such that coolant, lubricant, or other fluids can be delivered at different locations, at different flow rates, have their flow rates changed independently, and/or have their flow rates changed dynamically during a machining operation. In some embodiments, a feedback loop or input may be provided to obtain and/or provide information regarding the machining operation—such as cutting force, cutting temperature, cutting friction, machining operation, tool in use, work piece geometry, and/or material—and automatically and/or independently modify the fluid flow rates. The fluid may be atomized with air or other gases to minimize the quantities of fluid used. Components in the system may be modular to allow the system to be used with existing and new machining technologies.	07-17-2014

Aravindh Balaji, Sunnyvale, CA US

Patent application number	Description	Published
20140376802	Wafer Inspection Using Free-Form Care Areas - Methods and systems for detecting defects on a wafer are provided. One method includes determining characteristics of care areas for a wafer based on wafer patterns. Determining the characteristics includes determining locations of care areas, identifying at least one pattern of interest (POI) in the wafer patterns for each of the care areas, allowing any of the care areas to have a free-form shape, allowing the care areas to be larger than frame images and selecting two or more POIs for at least one of the care areas. The method also includes searching for POIs in images generated for the wafer using an inspection system. In addition, the method includes detecting defects on the wafer by determining positions of the care areas in the images and applying one or more defect detection methods to the images based on the positions of the care areas in the images.	12-25-2014

B.s. Balaji, Tamilnadu IN

Patent application number	Description	Published
20160117917	Physical and Logical Threat Analysis in Access Control Systems Using BIM - An apparatus including a building information model (BIM) of a secured area having a plurality of different portions, the BIM embodied in a memory, a processor that identifies portions of the secured area having different levels of security and a processor that alerts a user of a security weakness based upon an interaction between the security levels and physical characteristics of the secured area defined by the BIM.	04-28-2016

B. S. Balaji, Madurai IN

Patent application number	Description	Published
20150111536	System and Method for Visitor Guidance and Registration Using Digital Locations - A system including a smartphone or tablet of a visiting user accessing a web site and security system of a visited person, the security system having a secured area with the visited person located at a predetermined location within the secured area, the web site downloading an initial geographical location of the visiting user from the smartphone or tablet of the visiting user, a processor of the web site generating and sending a map to the smartphone or tablet based upon the downloaded initial geographic location of the visiting user and the predetermined location of the visited person, the smartphone or table displaying the generated map on a display of the smartphone or tablet guiding the visiting user from the initial location of the visiting user to the predetermined location of the visited person and the processor of the website dynamically updating the map displayed on the smartphone or tablet.	04-23-2015

Chandra Balaji, Bangalore IN

Patent application number	Description	Published
20140380460	Dynamic Communication Between Secure Endpoints - In one implementation, a hub and spoke network is made up of hub network devices and spoke network devices. A security protocol channel is established between the hub and at least a first spoke. The hub receives a resolution request from the first spoke via the security protocol channel. The resolution request includes data indicative of a second endpoint. The hub queries a next hop client database for a WAN address of the second endpoint. The first endpoint and the second endpoint are geographically separated nodes of the same enterprise network. The hub sends a resolution reply to the first endpoint including the WAN address for the second endpoint. The hub also sends a message to the second endpoint including a WAN address of the first endpoint and a summary of the data packet received at the first endpoint.	12-25-2014
20150150073	Smart Virtual Private Network - In one implementation, a policy server establishes a smart virtual private network between two client devices. The smart virtual private network includes a secure communication session using a security level or security algorithm that is variable and defined as a function of the two client devices. A first client device may generate a registration request including a first security configuration including the security level. Based on the registration request, the policy server generates a routing message that defines routing for communication from the first client device to a second client device. The routing message may update a routing table to associate the policy server with the second client device.	05-28-2015

D. Karthikeyan Balaji, Chennai IN

Patent application number	Description	Published
20100198950	Method to deliver services over existing wireless lan infrastructure - A method to bypass the existing pay and use model to deliver services over existing wireless LAN infrastructure between mobile terminal and server is disclosed. Many of the existing WLAN infrastructures require users to subscribe to service provider to access their network. The inventive method uses internet protocol (IP) packet for delivering services/data between server and mobile terminal. Internet protocol (IP) layer processes the IP packets received from a mobile terminal and uses protocol subfield in the IP header of the received IP packet in identifying the services/data at the server end. The server sends the IP packet containing requested services/data to the mobile terminal. Since all the communication takes place at IP layer (not TCP or UDP) it doesn't require user id and password to go through.	08-05-2010

Ekambaram Balaji, Portland, OR US

Patent application number	Description	Published
20080244491	Generic methodology to support chip level integration of IP core instance constraints in integrated circuits - A method and apparatus are provided for generating and using timing constraints templates for IP cores that can be instantiated in an integrated circuit design. The templates include a plurality of timing constraint statements for inputs and outputs of the respective IP core. At least one of the statements includes a configurable variable, wherein the timing constraints template is configurable through the variable for each of a plurality of instances of the IP core in the integrated circuit design.	10-02-2008

Gopalan V. Balaji, Kennett Square, PA US

Patent application number	Description	Published
20080255663	Artificial Cornea and Method of Making Same - The present invention is an artificial cornea designed to restore vision in patients who are not candidates to receive a natural cornea transplant (allograft). The present device construction involves the use of a biocompatible, non-porous optic disk intimately bonded to one or more anchoring layers of porous polymeric material, and a unique sealing region which enhances sealing of the artificial cornea in the recipient's eye.	10-16-2008

Holur Balaji, Bangalore IN

Patent application number	Description	Published
20080219224	System and Method for Providing Secure Mobility and Internet Protocol Security Related Services to a Mobile Node Roaming in a Foreign Network - A method for connection roaming a Mobile Node (MN) to a Network GateWay (NGW) for providing secure data path using Internet Protocol (IP) security procedure. Also Mobile IP (MIP) is required for providing mobility to the user, when the MN moves from one sub-network to another. However, when the Home Address of the network is not known, a cyclic interdependency is observed between the IP Security (Ipsec) procedures and MIP procedures. If the home address of the MN is not known initially during the procedure, IPsec Security Associations (SA's) are formed between the MN and NGW such that only MIP packets are passed through. After the MIP Registration is completed, the Home Address of the MN is known from the MIP registration Reply. MN now forms a data path tunnel with the NGW by exchanging Create_Child_SA messages.	09-11-2008

Jayakumar Balaji, Pallavaram IN

Patent application number	Description	Published
20130067105	SIP INTERFACE FOR MEDIA RECORDING VIA INAP - A SIP interface for media recording via INAP is disclosed. The present invention relates to SIP networks and, more particularly, to recording messages in SIP networks. Existing recording mechanisms offer only audio and fax based recording services to user for making announcements. Also, existing mechanisms would require a unique announcement ID for every type of media format recorded in the announcement. Thus, the options offered for the users are limited and poses difficulty to the user to enter different announcement ID's for every format. The present invention provides mechanisms wherein users can record announcements using different media types. Media types supported by a media server such as audio, text, video or combination of them may be employed in the recording. In addition, the mechanism provides a single announcement ID which can be employed for recording different media types. Thus, user is provided with options for recording service.	03-14-2013

Jayakumar Balaji, Guindy IN

Patent application number	Description	Published
20130003722	VOICE COMMUNICATION OF DIGITS - The present invention relates to SIP networks and, more particularly, to digit collection in SIP networks. The SIP user communicates the digits to a Media Server through voice/speech. The Media Server collects the digits and checks to determine if the digits satisfy required Dual Tone Multi Frequency rules. The Media Server plays a prompt message to the SIP user to indicate start of session to collect the digits and the SEP user says character(s) to indicate that the SIP user has completed saying the digits.	01-03-2013
20130205354	VCR CONTROL CAPABILITIES FOR INFORMATION PLAY SESSIONS - The present invention relates to communication networks and, more particularly, to information playback in communication networks. System and method for enabling Video Cassette Recording controls while information is being played to a user. A Media Gateway Controller indicates to a Media Server that the user could exercise Video Cassette Recording controls on the information while the information is being played to the user. The Media Server plays the information to the user and receives a Video Cassette Recording control command entered by the user. The Media Server performs an action on the information according to the Video Cassette Recording control command. The user is an Intelligent Network Application Part (INAP)/Customized Applications for Mobile networks Enhanced Logic (CAMEL) user.	08-08-2013

Jayakumar Balaji, Chennai IN

Patent application number	Description	Published
20130148548	SUPPRESSION OF ANNOUNCEMENTS IN COMMUNICATION NETWORKS - Suppression of Announcements in Communication Networks. The present invention relates to communication networks and, more particularly, to announcements in communication networks. System and method for suppression of announcement made to a user in a communication network. A user requests to start a communication session with a second user in the network. A suppression of announcement indicator is added in Connect operation while the communication session is being established with the second user and the announcement is suppressed from being played to the user if the second user is unable to answer the request. The users may be IMS users and/or PSTN users belonging to the same network or different networks.	06-13-2013
20130170404	CONTROL CAPABILITIES FOR INFORMATION RECORDING SESSIONS - The present invention relates to Intelligent Networks and, more particularly, to information recording sessions in Intelligent Networks, a method for enabling control capabilities for information recording session with a user in an Intelligent Network, the network comprises a Media Gateway Controller, a Service Control Point and a Media Server. The Service Control Point sends the control capabilities to the Media Gateway Controller and the Media Gateway Controller maps the control capabilities to a control information message. The Media Gateway Controller sends the control information message to the Media Server and the Media Server controls the information recording session based on the control capabilities present in the control information message.	07-04-2013
20130174206	VCR CONTROL CAPABILITIES FOR INFORMATION PLAY SESSIONS - The present invention relates to IMS networks and, more particularly, to information recording sessions in IMS networks. System and method for enabling control options while information is being recorded from a user. A Media Gateway Controller sends the control options to a Media Server. The Media Server receives a control command from the user, wherein the control command is based on the control options and the Media Server performs an action on the information based on the control command. The user is an Internet Protocol Multimedia Subsystem (IMS) user. The Media Gateway Controller sends the control options to the Media Server in a Session Initiation Protocol (SIP) INFO message using Media Server Markup Language (MSML) format.	07-04-2013

Jayaprakash Balaji, Mumbai IN

Patent application number	Description	Published
20090086204	Fluorescence Correlation Microscopy with Real-Time Alignment Readout - This invention relates to a confocal fluorescence correlation microscope with real-time alignment read out. With this instrument it is possible to do confocal imaging together with the particle size determination at a chosen location in the specimen. In particular, this invention relates to a detector module with a fixed aperture and detection electronics that can be conveniently connected to an existing confocal or multiphoton microscope, near the base of the objective lens of the microscope. This detector splits a part of the signal and uses it to generate a spot on the confocal image. This shows the spot where an FCS measurement can be carried out, and the same signal can then be used to perform a fluorescence correlation measurement after parking the excitation beam of the confocal to that spot. No alignment step is necessary for obtaining the measurement.	04-02-2009

K. Balaji, Malaviya Nagar IN

Patent application number	Description	Published
20110184779	DYNAMIC ON-LINE LEARNING SYSTEM FOR ELECTRONIC COUPONS USING ON-LINE AUCTIONS - A system, method, and computer program product implementing the method for generating promotional scheme parameters for issuing redeemable electronic coupons, wherein the method comprises automatically obtaining market demand data from defined sources of online auctions, conducting online auctions using defined parameters for specified goods and/or services to obtain market demand data, and storing and analyzing the market demand data obtained from the online auctions or the conducted auctions to estimate demand and calculate promotion scheme parameters for issue of redeemable electronic coupons.	07-28-2011

Kamini Balaji, Sunnyvale, CA US

Patent application number	Description	Published
20150297864	DEVICES, SYSTEMS, AND METHODS FOR CONTROLLING ACTIVE DRIVE SYSTEMS - The present application is related to devices, systems, and methods for controlling active drive systems. In one embodiment, the drive system may include a first surface and a second surface for engaging an elongate member. The first and second surfaces may be attached to a drive mechanism to move the elongate member. The first surface may be slidable relative to the drive mechanism and may have a clearance between the drive mechanism and an end of the first surface during movement of the elongate member in a non-slip condition. A sensor may be associated with the first surface and may be configured to detect movement of the first surface in a slip condition.	10-22-2015

Kamini Balaji, Mountain View, CA US

Patent application number	Description	Published
20140276392	INPUT DEVICE FOR ROBOTIC CATHETER AND GUIDE WIRE SYSTEM - An input device for a robotic catheter system includes an inner member having a generally cylindrical shape and defining an axis, and an outer member coaxially disposed on the inner member and configured to rotate about and move along the axis defined by the inner member to control a position and orientation of at least one of a catheter and a guide wire. Rotating the outer member about the axis causes the catheter, the guide wire, or both, to rotate and wherein moving the outer member along the axis causes the catheter, the guide wire, or both, to advance or retract relative to a patient's body.	09-18-2014
20140276934	TOUCH-FREE CATHETER USER INTERFACE CONTROLLER - A command interpreter may be in communication with a wireless controller. The command interpreter may be configured to identify a reference location of the wireless controller, identify a second location of the wireless controller, and determine, based on the reference location and the second location, a sequence of instrument commands configured to adjust positioning of the instrument device.	09-18-2014

Kamini Balaji, San Francisco, CA US

Patent application number	Description	Published
20140276394	INPUT DEVICE FOR CONTROLLING A CATHETER - An input device includes a plurality of orientation blocks each representing a portion of a catheter assembly and a controller configured to determine an orientation of the plurality of orientation blocks relative to one another. The controller is further configured to output a control signal that causes a tip of a catheter assembly to adopt the orientation determined by the controller. A system includes an actuator configured to manipulate a position and orientation of the catheter assembly. The controller of the input device is configured to output a control signal to the actuator to make a tip of a catheter assembly adopt the orientation determined by the controller. The input device can be virtually represented on a computing device.	09-18-2014
20140276933	TORQUE-BASED CATHETER ARTICULATION - A robotic surgical system configured for the articulation of a catheter comprises an input device, a control computer, and an instrument driver having at least one motor for displacing the pull-wire of a steerable catheter wherein the control computer is configured to determine the desired motor torque or tension of the pull-wire of a catheter based on user manipulation of the input device. The control computer is configured to output the desired motor torque or tension of the pull-wire to the instrument driver, whereby at least one motor of the instrument driver implements the desired motor torque to cause the desired pull-wire tension to articulate the distal tip of the catheter. The present embodiment further contemplates a robotic surgical method for the articulation of a steerable catheter wherein an input device is manipulated to communicate a desired catheter position to a control computer and motor torque commands are outputted to an instrument driver. The robotic system may further comprise a torque sensor. The robotic system may also incorporate closed loop feedback in which data from the torque measuring device is used to ensure that the torque in the motor or tension in the pull-wire closely matches the motor torque command from the control computer.	09-18-2014
20150375399	USER INTERFACE FOR MEDICAL ROBOTICS SYSTEM - An exemplary illustration of a user interface for a medical robotics system may include multiple light sources configured to illuminate a gesture within a field of view. The user interface may further include multiple cameras, which have a field of view and are configured to generate a detection signal in response to detecting the gesture within the field of view. The user interface can also have a controller configured to generate a command signal based on the detection signal. The command signal may be configured to actuate an instrument driver, a display device, a C-arm configured or any combination thereof to perform a function mapped to the gesture.	12-31-2015

Kodumudi S. Balaji, Downingtown, PA US

Patent application number	Description	Published
20110021555	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORTER DOSING REGIMENS FOR TREATING ACTINIC KERATOSES - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	01-27-2011
20110207766	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.	08-25-2011
20120329823	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.	12-27-2012
20130210855	2 X 2 X 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	08-15-2013

Kodumudi S. Balaji, Lansdale, PA US

Patent application number	Description	Published
20110257216	2 x 2 x 2 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-20-2011
20110257217	3 x 3 x 3 WEEK TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-20-2011
20110257218	2 x 2 x 2 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-20-2011
20110257219	LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORUMLATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-20-2011
20110263633	UP TO SIX WEEKS TREATMENT REGIMEN FOR TREATING ACTINIC KERATOSES WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-27-2011
20110263634	LOWER DOSAGE STRENGTH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 2.5% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-27-2011
20110263635	METHOD OF TREATING ACTINIC KERATOSIS WITH 3.75% IMIQUIMOD CREAM - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-27-2011
20110263636	3 x 3 x 3 WEEK DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75 % IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara° 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-27-2011
20110263637	UP TO SIX WEEKS DOSING REGIMEN FOR TREATING ACTINIC KERATOSIS WITH PHARMACEUTICAL COMPOSITIONS FORMULATED WITH 3.75% IMIQUIMOD - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.	10-27-2011
20110319811	COMBINATION THERAPY WITH CRYOSURGERY AND LOW DOSAGE STRENGTH IMIQUIMOD TO TREAT ACTINIC KERATOSIS - The present invention is directed to the use of complementary or combination lesion-directed therapy, such as cryosurgery, and field-directed therapy, such as low dose imiquimod topical therapy with short durations, in combination to treat actinic keratosis (“AK”). In carrying out the present invention, the lesion-directed and field-directed therapies may be applied sequentially or concomitantly, in accordance with the present invention. The novel complementary or combination AK therapy contemplated by the present invention: (1) significantly improves clearance of cryosurgery-treated Aks; (2) treats subclinical AK lesions; (3) treats those visible AK lesions in excess of that cryosurgery can actually treat in a single treatment due to, e.g., patient tolerance, provider treatment limits and/or cryosurgery cost to the patient; and (4) enhances sustained clearance overall, as compared to mono AK lesion-directed therapy.	12-29-2011
20120035556	PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM - The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).	02-09-2012
20120289538	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.	11-15-2012
20120329824	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.	12-27-2012
20120329825	LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS - Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2 methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.	12-27-2012
20140206735	HIGH DOSAGE TOPICAL METRONIDAZOLE AQUEOUS-BASED GEL FORMULATIONS AND THEIR USE TO TREAT ROSACEA - The present disclosure provides aqueous-based gel formulations of metronidazole useful for a variety of purposes, including topical application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with rosacea.	07-24-2014
20150314115	PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM - The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation (“pump systems”) and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).	11-05-2015

Kodumudi S. Balaji, Landsdale, PA US

Patent application number	Description	Published
20130005785	METHODS OF TREATING BACTERIAL VAGINOSIS WITH AQUEOUS-BASED METRONIDAZOLE GEL FORMULATIONS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.	01-03-2013
20130005787	HIGH DOSAGE MUCOADHESIVE METRONIDAZOLE AQUEOUS-BASED GEL FORMULATIONS AND THEIR USE TO TREAT BACTERIAL VAGINOSIS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.	01-03-2013

Kolmudi S. Balaji, Landsdale, PA US

Patent application number	Description	Published
20160106714	AQUEOUS-BASED METRONIDAZOLE GEL FORMULATIONS - The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.	04-21-2016

Mahesh Balaji, Chennai IN

Patent application number	Description	Published
20140289391	FRAMEWORK FOR FACILITATING IMPLEMENTATION OF MULTI-TENANT SAAS ARCHITECTURE - A framework for implementing multitenant architecture is provided. The framework comprises a framework services module which is configured to provide framework services that facilitate abstraction of Software-as-a-Service (SaaS) services and crosscutting services for a Greenfield application and a non SaaS based web application. Further the abstraction results in a SaaS based multitenant web application. The framework further comprises a runtime module configured to automatically integrate and consume the framework services and APIs to facilitate monitoring and controlling of features associated with the SaaS based multitenant web application. The framework further comprises a metadata services module configured to provide a plurality of metadata services to facilitate abstraction of storage structure of metadata associated with the framework and act as APIs for managing the metadata. The framework further comprises a role based administration module that facilitates management of the metadata through a tenant administrator and a product administrator.	09-25-2014

Mrinal Singh Balaji, Huntsville, AL US

Patent application number	Description	Published
20120256785	SYSTEMS AND METHODS FOR CALIBRATING DUAL POLARIZATION RADAR SYSTEMS - A dual polarization radar system is calibrated based on real-time data measurements, such as measured horizontal and vertical reflectivities, Z	10-11-2012
20140210661	SYSTEMS AND METHODS FOR CALIBRATING DUAL POLARIZATION RADAR SYSTEMS - A dual polarization radar system is calibrated based on real-time data measurements, such as measured horizontal and vertical reflectivities, Z	07-31-2014
20160025841	SYSTEMS AND METHODS FOR CALIBRATING DUAL POLARIZATION RADAR SYSTEMS - A dual polarization radar system is calibrated based on real-time data measurements, such as measured horizontal and vertical reflectivities, Z	01-28-2016

Pavan Balaji, Chicago, IL US

Patent application number	Description	Published
20120265837	REMOTE DIRECT MEMORY ACCESS OVER DATAGRAMS - A communication stack for providing remote direct memory access (RDMA) over a datagram network is disclosed. The communication stack has a user level interface configured to accept datagram related input and communicate with an RDMA enabled network interface card (NIC) via an NIC driver. The communication stack also has an RDMA protocol layer configured to supply one or more data transfer primitives for the datagram related input of the user level. The communication stack further has a direct data placement (DDP) layer configured to transfer the datagram related input from a user storage to a transport layer based on the one or more data transfer primitives by way of a lower layer protocol (LLP) over the datagram network.	10-18-2012

Ramachandran Balaji, Bangalore IN

Patent application number	Description	Published
20100298402	STILBENE DERIVATIVES AS PSTAT3/IL-6 INHIBITORS - Described are novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These novel compounds can inhibit pSTAT3/IL-6 and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.	11-25-2010

Ramamurthy Balaji, Coimbatore IN

Patent application number	Description	Published
20120058398	PAN-PEO Gels with Improved Conductance and Solvent Retention - Disclosed are gel electrolytes comprising a polymer, which is polyacrylonitrile (PAN) and polyethylene oxide (PEO); a lithium salt; and a solvent, which is a carbonate solvent, a lactone solvent, or mixtures thereof.	03-08-2012

Ramamurthy Balaji, Tamilnadu IN

Patent application number	Description	Published
20110300450	POLYURETHANE GEL ELECTROLYTES WITH IMPROVED CONDUCTANCE AND/OR SOLVENT RETENTION - Disclosed are gel electrolytes comprising a polymer, which is a cross-linked polyurethane prepared from a poly(alkyleneoxide) triol and a diisocyanate compound; a lithium salt; and a solvent, which is a carbonate solvent, a lactone solvent, or mixtures thereof.	12-08-2011

Ravishankar Balaji, Mountain View, CA US

Patent application number	Description	Published
20150281839	BACKGROUND NOISE CANCELLATION USING DEPTH - An apparatus, system, and method for reducing noise by using a depth map is disclosed herein. The method includes detecting a plurality of audio signals. The method includes obtaining depth information and image information and creating a depth map. The method further includes determining a primary audio source from a number of audio sources in the depth map. The method also includes removing noise from the audio signals originating from the primary audio source.	10-01-2015

Rishi Sundarajan Balaji, Hyderabad IN

Patent application number	Description	Published
20130191184	Technique To Model Business Asset State Changes In Component Business Modeling - Component Business Model (“CBM”) software that can generate and maintain a CBM of an enterprise, with the CBM software including a state change identification module and a create state diagram module. The state change identification module identifies state changes in a Business Asset of the CBM. The create state diagram module creates a state diagram for the Business Asset based upon the changes identified by the state change identification module. In some embodiments, the Business Assets of the CBM for which state diagrams are created will be the predominant assets of Participating Business Components that are involved in a Business Scenario.	07-25-2013

Santhana Balaji, Cupertino, CA US

Patent application number	Description	Published
20130233762	ACCESSORY UNITS FOR CONSUMER ELECTRONIC DEVICES AND RELATED ASSEMBLIES AND METHODS - An accessory unit includes a front flap and a rear cover. The rear cover includes a recessed portion that defines a chamber and a frame that extends about an opening of the chamber. The chamber is configured to receive a consumer electronic device, and the frame is configured to hold the consumer electronic device therein. For example, the frame may define a multi-sided cross-section with an inner edge thereof configured to engage a chamfered edge of the consumer electronic device. The front flap may include segments formed from panels with folding regions therebetween, which allow the front flap to fold. Further, an end region of the front flap hingedly couples the front flap to the rear cover, such that the front flap may be moved between open and closed configurations.	09-12-2013
20150070840	Flexible Printed Circuit Cables With Service Loops and Overbending Prevention - An electronic device may have a signal cable formed from a flexible printed circuit. A service loop may be formed in the signal cable. The bend may be formed in a desired location on the flexible printed circuit by contraction of an elastic member having ends attached to the flexible printed circuit. The elastic member may be conductive to carry signals and provide shielding. Structures may be attached to the flexible printed circuit to promote bending in a desired location and direction. A crease or other bending promotion feature may be applied to the flexible printed circuit at a desired bend location. Overbending prevention structures such as overmolded elastomeric structures may be applied to the flexible printed circuit at the bend. Integral strain relief features may prevent overbending of the flexible printed circuit upon exiting the elastomeric structures. Overmolded structures may serve as protective bumpers.	03-12-2015

Santhana K. Balaji, Cupertino, CA US

Patent application number	Description	Published
20140043121	ACCESSORY DEVICE - A cover is described that is magnetically attached to a tablet device. The cover includes at least as flap. In the described embodiment, the flap includes a plurality of segments where the first segment includes a first plurality of edge attach magnets arrayed along a first edge of the flap and where a second segment includes a second plurality of edge attach magnets arrayed along a second edge of the flap opposite the first edge.	02-13-2014
20140043748	COVER FOR AN ELECTRONIC DEVICE - A cover is described that is magnetically attached to a tablet device. The cover includes at least as flap. In the described embodiment, the flap includes a plurality of segments where the first segment includes a first plurality of edge attach magnets arrayed along a first edge of the flap and where a second segment includes a second plurality of edge attach magnets arrayed along a second edge of the flap opposite the first edge.	02-13-2014
20140283979	METHODS FOR FORMING FIBER COMPOSITE STRUCTURES - An accessory unit includes a front flap and a rear cover. The rear cover includes a recessed portion that defines a chamber and a frame that extends about an opening of the chamber. The chamber is configured to receive a consumer electronic device, and the frame is configured to hold the consumer electronic device therein. For example, the frame may define a multi-sided cross-section with an inner edge thereof configured to engage a chamfered edge of the consumer electronic device. The front flap may include segments formed from panels with folding regions therebetween, which allow the front flap to fold. Further, an end region of the front flap hingedly couples the front flap to the rear cover, such that the front flap may be moved between open and closed configurations.	09-25-2014
20150076185	ACCESSORY DEVICE - A cover is described that is magnetically attached to a tablet device. The cover includes at least as flap. In the described embodiment, the flap includes a plurality of segments where the first segment includes a first plurality of edge attach magnets arrayed along a first edge of the flap and where a second segment includes a second plurality of edge attach magnets arrayed along a second edge of the flap opposite the first edge.	03-19-2015

Santhana Krishnan Balaji, Cupertino, CA US

Patent application number	Description	Published
20130256181	TRAY CONFIGURED FOR PACKAGING, PACKAGED PRODUCT ASSEMBLY, AND METHOD FOR PACKAGING A PRODUCT - A tray configured for packaging is provided. The tray may include a substantially planar portion and a curved perimeter portion extending from the substantially planar portion. One or more cutout portions may be defined in the substantially planar portion. The tray may also include a handle that may be grasped during insertion into, or removal from a rear cover of an accessory unit. In this regard, the substantially planar portion and the curved perimeter portion of the tray may support a recessed portion of the rear cover of the accessory unit when received therein. Thus, issues with respect to deformation of the recessed portion, which may be formed from a flexible material, may be avoided. The tray may be part of a packaging system that further includes a box and a lid.	10-03-2013
20140262008	HEATED ROLLER HEAD BONDING PROCESS - A laminating device for bonding a protective layer to a substrate, including a driver and a roller head having a shape with a contour to fit a geometric feature of the substrate, is provided. The roller head has a cylindrical symmetry with an axis; the laminating device includes a coupler for mechanically coupling the driver to the roller head. The coupler is parallel to the axis so that the driver provides a rotational motion and a liner displacement to the roller head. The driver also provides a bonding energy to the roller head through the coupler. A roller head for use in a laminating device as above is also provided. A method for bonding a protective layer to a substrate using a laminating device as above is also provided.	09-18-2014
20140272129	COMPLIANT PERMEABLE GLUE APPLICATOR - An adhesive applicator including an adhesive dispenser to provide adhesive at a pressure and a compliant head adapted to rotate about a symmetry axis is provided. The compliant head includes a permeable material to provide the adhesive to an adhesive layer on a top surface of a substrate. The adhesive applicator may include a driver coupled to move the compliant head so that the symmetry axis forms a trajectory on a substrate. An applicator head including a foam matrix having pores with a pre-selected pore diameter and having a compliant surface to accommodate substrate geometry is also provided. The foam matrix is elastically deformable upon contact with the substrate geometry. A method for applying an adhesive layer to a substrate using an adhesive applicator as above is also provided.	09-18-2014
20150065208	FEATURES AND MANUFACTURING METHODS FOR A CASE FOR A PORTABLE ELECTRONIC DEVICE - An accessory unit for use with an electronic device is described. Accessory unit includes a front flap and a rear cover. The rear cover includes a recessed portion that defines a chamber and a lip portion. The chamber is configured to receive a consumer electronic device, and the lip portion is configured to hold the consumer electronic device therein by an interference fit that exposes substantially all of a display portion of the consumer electronic product. The front flap can include segments formed from panels with folding regions therebetween, which allow the front flap to fold. Further, an end region of the front flap pivotally couples the front flap to the rear cover, such that the front flap may be moved between open and closed configurations. The front may include magnetic elements.	03-05-2015
20150076146	TRAY CONFIGURED FOR PACKAGING, PACKAGED PRODUCT ASSEMBLY, AND METHOD FOR PACKAGING A PRODUCT - A tray configured for packaging is provided. The tray may include a substantially planar portion and a curved perimeter portion extending from the substantially planar portion. One or more cutout portions may be defined in the substantially planar portion. The tray may also include a handle that may be grasped during insertion into, or removal from a rear cover of an accessory unit. In this regard, the substantially planar portion and the curved perimeter portion of the tray may support a recessed portion of the rear cover of the accessory unit when received therein. Thus, issues with respect to deformation of the recessed portion, which may be formed from a flexible material, may be avoided. The tray may he part of a packaging system that further includes a box and a lid.	03-19-2015
20150295615	CASE FOR AN ELECTRONIC DEVICE AND MANUFACTURING METHODS FORMAKING A CASE - An accessory unit includes a front flap and a rear cover. The rear cover includes a recessed portion that defines a chamber and a lip that extends about an opening of the chamber. The chamber is configured to receive a consumer electronic device, and the lip is configured to hold the consumer electronic device therein. The rear cover can include a shell formed from glass fiber reinforced plastics and a lip formed from a thermoplastic. The front flap may include segments formed from panels with folding regions therebetween, which allow the front flap to fold. Further, an end region of the front flap hingedly couples the front flap to the rear cover, such that the front flap may be moved between open and closed configurations. Methods of manufacturing the accessory unit are also disclosed.	10-15-2015

Senthil Balaji, Tallahassee, FL US

Patent application number	Description	Published
20140288847	SYSTEMS AND TECHNIQUES FOR SEGMENTATION OF SEQUENTIAL DATA - An efficient method and associated systems for segmentation of high throughput sequential data, such as genomic datasets. The technique first utilizes dynamic programming to compute the significance for a large number of candidate segments. It then uses tree-based data structures to detect overlapping significant regions and update them simultaneously. Refinement and merging of significant segments are performed at the end to generate the final segmentation.	09-25-2014

Srinath Balaji, Bangalore IN

Patent application number	Description	Published
20110070161	ACTIVE ENANTIOMER - The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of said precursor compound and said PET tracer. Also provided by the present invention is a radiopharmaceutical composition comprising the PET tracer of the invention. Methods for using the PET tracer and the radiopharmaceutical composition are also provided.	03-24-2011
20130121926	DYE COMPOSITIONS AND DYE SYNTHESES - The present invention relates to sulfonated optical dye compositions, especially dyes suitable for biological applications in vitro, and for in vivo imaging. Improved dye compositions and intermediates are provided, which enable the suppression of undesirable newly-identified impurities. Also provided is the use of the improved dye compositions in the preparation of conjugates with biological targeting molecules.	05-16-2013

Srinath Balaji, Karnataka IN

Patent application number	Description	Published
20140135531	PRECURSOR COMPOUNDS AND METHODS FOR MAKING SAME - The present invention relates to a method of obtaining radiopharmaceutical precursors, and in particular precursors to protected amino acid derivatives, which are used as precursors for production of radiolabelled amino acids for use in in vivo imaging procedures, such as positron emission tomography (PET).	05-15-2014
20150133663	NOVEL SYNTHESIS METHOD - The present invention relates to a method of making compounds having affinity for the 1 A subtype of the serotonin receptor, i.e. 5HT	05-14-2015

Srinath Balaji Aralikatti Prahladachar Balaji, Harapanahali IN

Patent application number	Description	Published
20150335766	CRYSTALLIZATION PROCESS OF TRICYCLIC INDOLE DERIVATIVES - A composition comprising a tricyclic indole compound. The composition has a higher purity and better impurity profile than known compositions comprising said tricyclic indole compound and as a consequence has superior properties, particularly when said compound is destined for use in vivo as a therapeutic or diagnostic agent.	11-26-2015

Sundara Kalyana Balaji, Vadodara IN

Patent application number	Description	Published
20140374284	NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE - The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.	12-25-2014
20150175526	THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE - The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.	06-25-2015

Swathi Balaji, Cincinnati, OH US

Patent application number	Description	Published
20150037279	SUSTAINED RELEASE FORMULATION OF INTERLEUKIN-10 FOR WOUND TREATMENT AND RELATED METHODS - A sustained release formulation of interleukin-10 for wound treatment and related methods is provided.	02-05-2015

Vembu Balaji, Folsom, CA US

Patent application number	Description	Published
20140157410	Secure Environment for Graphics Processing Units - In accordance with some embodiments, a protected execution environment may be defined for a graphics processing unit. This framework not only protects the workloads from malware running on the graphics processing unit but also protects those workloads from malware running on the central processing unit. In addition, the trust framework may facilitate proof of secure execution by measuring the code and data structures used to execute the workload. If a part of the trusted computing base of this framework or protected execution environment is compromised, that part can be patched remotely and the patching can be proven remotely throughout attestation in some embodiments.	06-05-2014